Area of research
Immunology · Hematology
Research interest
Research interests include Immunodeficiency and Autoimmune Disorders, Hematopoietic Stem Cell Transplantation, Immune Cell Function and Interaction, and CAR-T cell therapy research.
MIF functional polymorphisms are associated with acute GVHD progression and steroid-refractoriness
Trajectories from single-cells to PAX5-driven leukemia reveal PAX5-MYC interplay in vivo
Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)
Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Wiskott-Aldrich syndrome: a study of 577 patients defines the genotype as a biomarker for disease severity and survival
Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis
Management of Atopy with Dupilumab and Omalizumab in CADINS Disease
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma
Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines
Genotype-phenotype correlations in chronic granulomatous disease: insights from a large national cohort
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.
Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial
Early lymphocyte collection for <scp>anti‐CD19 CART</scp> production improves T‐cell fitness in patients with relapsed/refractory diffuse large B‐cell lymphoma
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Clonal Myeloid Dysplasia Following CAR T-Cell Therapy: Chicken or the Egg?
Early lymphocyte collection for anti-CD19 CART production improves T-cell fitness in patients with relapsed/refractory diffuse large B-cell lymphoma.
High rate of adenovirus detection in gastrointestinal biopsies of symptomatic stem cell transplant recipients
Sclerotic-Type Cutaneous Chronic Graft-Versus-Host Disease Exhibits Activation of T Helper 1 and OX40 Cytokines
Combined Immunodeficiency Caused by a Novel Nonsense Mutation in LCK
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study
Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party
Risk and promise: an 11-year, single-center retrospective study of severe acute GVHD in pediatric patients undergoing allogeneic HSCT for nonmalignant diseases